Biolargo Stock Price, News & Analysis

BioLargo (OTCQX: BLGO) announced its participation in the 17th annual LD Micro Main Event on October 29th at 3:00 PM PT at the Luxe Sunset Boulevard Hotel in Los Angeles. Dennis P. Calvert, President and CEO, will present the company's plans for commercializing their Cellinity™ battery energy storage technology through a partner-centric business model. The event runs from October 28th-30th, featuring approximately 150 companies presenting in half-hour slots and conducting private investor meetings. The company recently validated key performance metrics of its safe, long-lasting battery technology.

BioLargo, Inc. (OTCQX:BLGO) has announced successful preliminary internal testing of its Cellinity battery technology, confirming key performance metrics. The tests verified the stability of the battery cell chemistry, reliability of the sealed, non-venting cell design, and its ability to quickly charge and discharge at high voltage. Cellinity is positioned as a superior alternative to lithium-ion batteries for long-duration energy storage applications, offering advantages in safety, sustainability, longevity, and energy density.

The company is now proceeding with third-party validation testing at acclaimed facilities to further assess Cellinity's electrochemical performance. BioLargo is also advancing the development of larger format 'Spartan' Cellinity cells and battery modules. The announcement highlights the significant market potential for energy storage solutions, with global supply projected to reach over 5 terawatts by 2050 and market value estimates between $1-3 trillion by 2040.

BioLargo (OTCQX:BLGO) announced a ribbon-cutting ceremony for its pilot-scale manufacturing facility for Cellinity, its next-generation battery energy storage technology. The invite-only event will be held on September 21, 2024, at BioLargo's facilities in Oak Ridge, Tennessee.

Cellinity is designed for safe, environmentally conscious large-format long-duration battery energy storage for applications including grid-scale storage, renewable energy storage, and EV charging stations. The event will feature a facility tour and presentations on how Cellinity batteries could improve renewable energy storage and grid reliability.

BioLargo will also present a new prototype scaled-up version of its Cellinity battery cells. The company is working towards a 'sell factories, not batteries' business model, with potential international partners from Norway attending the event.

BioLargo's subsidiary, Clyra Medical Technologies, has appointed Dr. Steven J. Kavros as its new Chief Medical Officer. Dr. Kavros brings extensive experience in advanced wound healing and limb preservation, having spent over 20 years at the Mayo Clinic. He has a strong background in research, medical education, and the medical device industry. Dr. Kavros has given over 1,800 presentations at conferences and authored numerous peer-reviewed papers. His expertise includes successfully bringing multiple products to market in wound healing, limb preservation, and orthopedics. Clyra CEO Steve Harrison believes Dr. Kavros' clinical expertise and business insight will be important for the company's manufacturing and distribution plans for its Bioclynse product.

BioLargo, Inc. (OTCQX:BLGO), a sustainable technology developer and environmental engineering company, has announced an investor webcast and conference call scheduled for Wednesday, August 14, 2024, at 1:30 PM Pacific Time. The event will review the company's financial results for Q2 2024, discuss recent milestones, and include a Q&A session. Participants can join via webcast or teleconference, with replay options available until August 28 for teleconference and November 14 for webcast. This event provides an opportunity for investors and the public to gain insights into BioLargo's performance and future outlook.

BioLargo, Inc. (OTCQX:BLGO), a cleantech company, reported record quarterly revenue of $5 million for Q2 2024, a 247% increase compared to Q2 2023. The company's revenue for the first six months of 2024 grew by 88% compared to the same period in 2023. Despite the revenue growth, BioLargo recorded a net loss of $780,000 for the quarter, including $540,000 in non-cash stock option compensation expense. As of June 30, 2024, the company had $4.8 million in cash and cash equivalents, with total assets of $10.1 million and stockholder's equity of $5.9 million. CEO Dennis P. Calvert expressed confidence in the company's position to advance the commercialization of its cleantech products and services. The final quarterly report is expected to be filed by August 14, 2024, with an earnings conference call scheduled for the same day.

BioLargo, a company focused on sustainable technologies, announced its engineering subsidiary secured a subcontract to provide air quality services to two Arizona U.S. Air Force bases. This contract, worth approximately $812,000 annually, follows another recent contract for three New Mexico Air Force bases, generating an average annual revenue of $650,000. BioLargo's total monthly revenue from these contracts exceeds $100,000. The four-year prime contract ensures pricing but does not guarantee continuation. BioLargo's services include air quality regulatory compliance under the Fence-to-Fence (F2F) support contract through HLTLI Joint Venture.

BioLargo's subsidiary, Clyra Medical Technologies, has selected Keystone Industries to support the manufacturing of its medical products, specifically the Bioclynse surgical wound irrigation solution. Bioclynse is FDA 510(k) cleared, non-cytotoxic, and effective against biofilms, presenting significant benefits for patient outcomes in surgeries and dentistry. Keystone, a global manufacturer with over a century of experience, has committed significant investment in infrastructure to scale up production. Both companies have emphasized the importance of this collaboration for the successful market launch of Bioclynse.

BioLargo (OTCQX:BLGO) has successfully manufactured its first Cellinity™ 'Liquid Sodium' prototype battery cells. The Cellinity battery platform aims to provide safer, long-lasting, and environmentally friendly energy storage alternatives to lithium-ion batteries. These prototype cells will undergo testing and validation to confirm performance claims. Cellinity batteries boast several advantages: safety (no fire or explosion risk), longevity (no performance drop after thousands of cycles), high energy density, and the use of North American-sourced materials without rare-earth elements. Future plans include manufacturing full-scale prototype modules and exploring financing options, focusing on community-based partnerships.